Immunome CMO Robert Lechleider Exercises Options and Sells Shares Under 10b5-1 Plan

Immunome Inc. Chief Medical Officer Robert Lechleider filed a Form 4 disclosing significant stock transactions on July 2, 2026. Lechleider exercised 55,000 employee stock options at $8.73 per share, acquiring the same number of common shares. Concurrently, he sold 54,999 shares across three separate transactions at weighted average prices of $21.95, $22.76, and $23.44 per share. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 26, 2026. Following these transactions, Lechleider's holdings decreased from 70,805 to 15,805 common shares, while his remaining unexercised options stand at 290,000. The transactions represent a significant reduction in direct common stock ownership while maintaining substantial option positions.